Background
UniProt entry P02545 has emerged as a putative target candidate in ovarian carcinoma, a malignancy with high mortality and limited effective treatment options. This protein is represented in multiple gene expression profiling studies of ovarian carcinoma, indicating a potential role in tumor biology. Despite its presence in these datasets, P02545 has not been linked to any registered clinical development programs in this indication, positioning it as a hypothesis-generating candidate warranting further experimental validation to elucidate its biological and therapeutic relevance.
Data-mining rationale
The identification of P02545 as a candidate target resulted from cross-referencing UniProt’s reviewed human protein entries annotated for ovarian carcinoma against 686 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). Several GEO datasets (GDS:200333343, GDS:200322784, GDS:200301530, GDS:200319500, GDS:200315735) include expression data for P02545 in ovarian carcinoma samples. This integrative data-mining approach highlights P02545 as recurrently expressed in ovarian carcinoma contexts, suggesting a potential involvement in disease biology worthy of further investigation.
Why prior analyses may have missed this
Many of the GEO datasets containing P02545 expression data were generated before the adoption of advanced empirical-Bayes statistical methods such as limma, which enable more accurate differential expression analysis with rigorous multiple-testing corrections like the Benjamini-Hochberg false discovery rate. Earlier analyses may have lacked sufficient statistical power or correction, leading to under-recognition of P02545 as a significant gene in ovarian carcinoma. Additionally, the absence of clinical programs targeting P02545 suggests it has not been prioritized for translational research, contributing to its current status as an overlooked candidate.
Reasoning for further validation
To assess the potential relevance of P02545 in ovarian carcinoma and its suitability as a therapeutic target, the following experimental steps are recommended:
- Re-analysis of GEO datasets: Apply limma with Benjamini-Hochberg false discovery rate correction to the matched ovarian carcinoma microarray datasets to robustly determine differential expression of P02545.
- Independent validation: Confirm P02545 expression patterns by quantitative PCR in an independent cohort of ovarian carcinoma patient samples.
- Tissue specificity assessment: Examine P02545 expression across normal and tumor tissues using resources such as GTEx and the Human Protein Atlas to understand its distribution and potential off-target effects.
- Pathway and interaction analysis: Utilize protein interaction and pathway databases like STRING and OmniPath to contextualize P02545 within molecular networks relevant to ovarian carcinoma.
- Druggability evaluation: If supported by expression and pathway data, assess the druggability of P02545 through databases such as DGIdb and ChEMBL to identify potential modulators.
These investigations will provide critical insights into whether P02545 represents a viable and novel target for therapeutic intervention in ovarian carcinoma.